Replies to post #95092 on Biotech Values

[sdtrond]

Jesse,

Believe me, I know what you mean about brevity and posts, I shoot from the hip much too often myself. Thanks for the reply.

Yes, Medicare reimbursement will be central to success. But I take it as a tenet of faith that at least through 2014, it will be business as usual. So with approval, Medicare should be paying for Provenge, without a whimper.

And why not? I'll throw this out: with the label they have they can administer this before Taxotere. With the relative cost between the two at ~$60K for Tax and ~$93K for Provenge, it seems to me with the benign side effect profile and possible long term delay of any kind of chemo that most doctors and patients will elect Provenge.

By the time the PPA really comes into force and they start looking at cost/benefit, I think Provenge will have proven its own. If we disagree there, then we'll have to disagree.

Regards,
Trond